About the project:
PragmaClin Research Inc., based in St. John’s, Canada, is a digital healthcare company developing PRIMS, a tool that leverages depth cameras and machine learning to assess Parkinson’s Disease progression.
Currently undergoing regulatory approval and clinical validation, PragmaClin is gearing up for international expansion. OCO Global was commissioned as their market partner due to its strong foothold in relevant European markets and in-house expertise. OCO’s role involved identifying the top three European markets for entry, formulating a regulatory and commercial strategy, and seeking collaborations with European neurologists to facilitate further trials and identify funding opportunities.
How OCO Global supported:
OCO Global provided strategic support to PragmaClin as they navigated Europe’s complex healthcare landscape. We developed a detailed market report highlighting key regions such as the Netherlands, Ireland, and Scandinavia. This report offered valuable insights into the treatment of Parkinson’s disease and emerging medical device trends, enabling PragmaClin to better understand the challenges and needs faced by European neurologists.
Our team also guided PragmaClin through the European Medical Device Regulation (MDR) process, ensuring they are well-positioned to meet regulatory standards. Additionally, we facilitated connections with essential partners to streamline their journey towards compliance and market entry.
Results:
Within the 4-month program, OCO Global facilitated outreach to 35 relevant organizations, securing nine critical meetings that provided valuable insights into conducting validation trials. Additionally, we enabled PragmaClin to join a funding application in Norway and explore participation in clinical trials, positioning the company to advance their product from development to commercial success in Europe.
